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Characterization of innate immune viral
sensors in patients following allogeneic
hematopoietic stem cell transplantation
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Abstract
Viral infection is a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplant
(HSCT), with up to one in four deaths directly linked to viral disease. Whilst awaiting lymphocyte reconstitution
post-HSCT, the innate antiviral immune response is the first line of defense against invading viruses. Several novel
innate viral-sensing pathways have recently been characterized, but their physiological importance in humans is poorly
understood. We analyzed a panel of innate viral-sensor genes in HSCT patients, and assessed whether differences in
innate antiviral responses could account for variation in susceptibility to viral infections. Expression levels of innate viral
sensors in HSCT patients with active viral infections, HSCT patients without active infections and healthy volunteers
were highly homogenous. Although IFN-a expression was up-regulated in actively infected patients relative to controls,
a corresponding up-regulation of innate viral sensor expression was not observed. IFN-a stimulation of patient PBMCs
in vitro showed intact IFN-a signaling, but actively infected patients’ PBMCs had reduced up-regulation of innate viral
sensors. We show that the aberrant IFN-a responses in HSCT patients were not due to calcineurin inhibition. Our data
therefore raises the possibility of an intrinsic defect in innate viral sensor up-regulation in HSCT patients following
viral infection.
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Introduction
Allogeneic hematopoietic stem cell transplantation
(HSCT) is an established treatment for hematological
malignancies and certain bone marrow defects. All
patients receiving allogeneic HSCT experience a pro-
longed period of compromised immunity, owing to
the long time (up to 1 yr) taken for reconstitution of a
functional lymphocyte population by the donor bone
marrow, combined with concurrent use of immunosup-
pressive drugs that further suppress T-lymphocyte
activity. Studies commonly report virus infections to
occur in up to around 40% patients post-HSCT in
both the pediatric and adult setting,1–4 with reported
mortality ranging from 10% to 50%.4 A signiﬁcant
proportion of viral infections are caused by reactivation
of herpesviruses [predominantly cytomegalovirus
(CMV) and Epstein–Barr virus (EBV)]. Infection by
adenovirus and numerous respiratory viruses also con-
tribute to poor patient outcome.1
A number of risk factors have been linked to
increased viral infection and higher transplant-related
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mortality in patients following allogeneic HSCT.
Donor selection plays an important role. For example,
mismatch between recipient and donor CMV serostatus
has been associated with increased infections, and
a higher transplant-related mortality in unrelated allo-
geneic HSCT.5,6 Recipient and treatment characteris-
tics that delay or impair immune reconstitution also
increase the risk of viral infections post-HSCT.7
These factors include recipient age and comorbidity,
signiﬁcant pretreatment immunosuppression, e.g.
ﬂudarabine, higher conditioning intensity, T-cell-
depletion strategies, e.g. alemtuzumab, graft versus
host disease (GvHD) and immunosuppression after
the transplant. However, these risk factors do not
allow accurate prediction of all HSCT patients that
succumb to viral infection, suggestive of additional
undeﬁned variation between patients.
Over the past decade, many intracellular antiviral
pathways intrinsic to all mammalian cells have been
elucidated. These include identiﬁcation of several
novel mechanisms of detecting the invading virus in
the host cell cytoplasm. For viruses commonly infecting
HSCT patients, the innate immune recognition path-
ways of particular interest are the cGAS-STING axis
capable of recognizing double-stranded DNA from
human herpesviruses and adenovirus,8–10 the RIG-I
pathway for detection of viral double-stranded RNA
and 5’PPP-RNA from viruses such as human inﬂuenza
and parainﬂuenza,11,12 and the intracellular immuno-
globulin receptor TRIM21, which identiﬁes invading
viruses tagged by Abs.13 The antiviral sensing pathways
are known to be up-regulated by IFN-a, and a major
downstream eﬀector mechanism from the viral sensors
is to further increase the expression of IFN-a, thus
forming a positive-feedback loop during a viral infec-
tion.14 In conjunction with up-regulation of these viral
sensors, IFN-a also induces the expression of hundreds
of genes collectively known as IFN-stimulated genes
(ISGs) that allow both virally infected and bystander
cells to mount an antiviral immune response.15
The role of the many innate viral sensors has been
extensively characterized in vitro and in animal models.
For example, mice deﬁcient in cGAS, RIG-I or TRIM21
rapidly succumb to viral infections,10,16–18 showing
these innate sensor mechanisms play a vital role in
defense against virus infections. However, in humans
the relative contribution of many of these ISGs com-
pared with adaptive immune responses against virus
infections is poorly understood, with few ISGs so far
shown to control virus infections in humans.14
Following HSCT, monocytes play an important
early role in protection against infection. Their recon-
stitution is faster than lymphocytes (30 d vs. up to 1 yr),
and a delay in monocyte recovery has been associated
with an increased frequency of infection complications,
as well as a poorer overall survival rate.19,20 Activation
of monocytes in the face of viral infection ﬁrst requires
recognition of the invading pathogen via the innate
immune sensors. We hypothesize that dysregulation
of the innate immune virus sensors could account for
variation in susceptibility to virus infection following
HSCT treatment.
To this end, we assessed the innate viral sensing
pathways and cytokine proﬁle produced by monocytes
in HSCT patients with and without active viral infec-
tions, as well as healthy volunteers. Our results did not
show a consistent relationship between up-regulation of
IFN-a and expression of the viral sensors in HSCT
patients. Intact IFN-a signaling pathways were demon-
strated in patient PBMCs and shown not to be aﬀected
by immunosuppressive therapy, but actively infected
patients had reduced up-regulation of the innate viral
sensors vs. patients without active infections or healthy
volunteers. Our study provides the ﬁrst insight into the
intracellular antiviral immune responses of patients
that have received HSCT, and shows IFN-a signaling
to be heterogeneous and complex in this patient cohort.
Materials and methods
Patient recruitment and sample collection
Peripheral whole-blood samples were collected into
EDTA tubes from both patients and healthy volunteer
adult donors. Ethical consent for the study was
approved by the Research Ethics Committees for each
donor group separately; HSCT patients (REC 07/
MRE05/44), patients with primary immunodeﬁciency
receiving regular immunoglobulin therapy (‘PI
patients’) (REC 12/WA/0148); and healthy volunteers
(16/LO/0997). All participants were older than 18 yr
and gave written informed consent. Samples were
anonymized at point of collection by the phlebotomist.
Patients were recruited from Addenbrooke’s Hospital,
Cambridge University Hospitals NHS Foundation
Trust, and healthy volunteers were recruited from the
Medical Research Council Laboratory of Molecular
Biology. All HSCT patients recruited were within 1 yr
of receiving the HSCT. PI patients were recruited if
they were receiving immunoglobulin therapy, either
intravenously or subcutaneously for 1mo or longer.
Leukocyte diﬀerential counts were performed on a
Siemens ADVIA2500i platform by the Department of
Haematology clinical laboratory at Addenbrooke’s
Hospital.
Transplantation protocols
The transplantation protocols were approved by the
local research ethics committee and informed consent
was obtained from all patients. Human leukocyte Ag
(HLA) typing of recipients and donors was carried out
by high-resolution molecular techniques. The selection
of conditioning regimen and source of hematopoietic
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stem cells were based on hematological diagnosis,
donor availability and clinical state of the patient.
GvHD prophylaxis for standard conditioning regimens
consisted of lymphodepletion by alemtuzumab or
antithymocyte globulin (ATG), or methotrexate in the
conditioning regimen, with a calcineurin inhibitor
(ciclosporin/tacrolimus) administered for a minimum
of 6mo and tapered thereafter. In reduced-intensity
conditioning regimens, the GvHD prophylaxis was
lymphodepletion by alemtuzumab ATG, and a calci-
neurin inhibitor, administered from d 1 and tapered
from d 56 for sibling transplants and d 70 for matched
unrelated transplants in the absence of GvHD. For
haploidentical transplants, the GvHD prophylaxis con-
sisted of cyclophosphamide, mycophenolate mofetil
and tacrolimus. Chimerism analysis was performed
routinely on d 28, 56, 100, then 6mo after HSCT
using SNP analysis. Red cells and platelets were trans-
fused to maintain hemoglobin level and platelet count
above 80 g/l and 10 109/l, respectively. All patients
received antiviral and antifungal prophylaxis using
aciclovir and a triazole agent or AmBisome.
Prophylaxis with azithromycin was given to donors or
recipients with serological evidence of toxoplasma
exposure. All patients were monitored weekly for
CMV, EBV and adenovirus DNA. Monitoring for add-
itional viruses, e.g. respiratory viruses, BK, JC and nor-
ovirus, was carried out based on patient clinical status.
Isolation, storage and fractionation of PBMCs
PBMCs were puriﬁed from whole-blood samples using
the standard Ficoll gradient technique within 4 h of
collection. Brieﬂy, 20ml whole blood was layered
over 20ml Histopaque 1077 (Sigma-Aldrich, St.
Louis, MO, USA) and centrifuged at 600 g for
30min. The PBMC interface was carefully removed
by pipetting and washed with PBS by centrifugation
at 300 g for 10min. PBMCs were counted and 1 107
cells were cryopreserved in 10% DMSO and 40% FCS.
CD14+ monocytes were enriched from the remaining
PBMCs using magnetic-activated cell sorting (MACS
MicroBeads; Miltenyi Biotec, Bergisch Gladbach,
Germany) according to the manufacturer’s instruc-
tions. Monocyte enrichment was necessary because
ﬂow cytometry data (data not shown) revealed variabil-
ity in leukocyte diﬀerential composition between HSCT
patients, and preliminary results showed variation in
gene expression between CD14+ and CD14– cells.
RNA extraction and quantitative real-time PCR
RNA was extracted from freshly isolated CD14+
monocytes using an RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s
instructions. The yield and purity of RNA were deter-
mined by spectrophotometric measurements of the
ratio of UV absorbance at 260 and 280 nm by a
Nano-drop 2000 (Thermo Fisher Scientiﬁc, Waltham,
MA, USA). RNA was then stored at –80C until use.
RNA was extracted from CD14+ monocytes of each
subject at a concentration >20 ng/ll.
CD14+ monocyte RNA was reverse transcribed
using Super RT reverse transcriptase (HT
Biotechnology, Cambridge, UK). cDNA was then used
for quantitative PCR (qPCR) on an AB Biosystems
StepOnePlus machine with a panel of Taqman-based
primer probes (Thermo Fisher Scientiﬁc) with the fol-
lowing cycling conditions for 40 cycles: 95C for 1 s,
60C for 20 s. Following analysis of four widely used
house-keeping genes (b-actin, HPRT, TBP and
RPLP0), the most stable house-keeping gene in samples
obtained from healthy volunteers was determined to be
b-actin. Gene ampliﬁcations were therefore normalized
to b-actin and subsequently the delta-delta CT method of
analysis was conducted with reference to gene expression
in the healthy volunteer samples. Only patients with
detectable IFN-a levels were compared by the delta-
delta CT method of analysis to healthy volunteers.
In vitro stimulation of PBMCs
Cryopreserved PBMCs from patients and healthy con-
trols were thawed, washed, plated at 0.5 106/well and
rested overnight at 37C in RPMI, supplemented with
10% FCS and 250U/ml penicillin, and 250 lg/ml
streptomycin. Cells were then stimulated with 1000 IU
IFN-a or PBS control for 6 h. Where indicated, tacro-
limus (LKT Laboratories, St. Paul, MN, USA) was
added to cells 2 h prior to IFN-a stimulation at
10-100 ng/ml. Following stimulation, cells were har-
vested for RNA extraction and quantitative real-time
PCR (qRT-PCR) as previously described.
Statistics
P-Values were calculated using the v2test.
Results
Patient characteristics
Whole-blood samples were collected from 15 patients
that had received HSCT between February 2015 and
September 2016 at Addenbrooke’s Hospital,
Cambridge University Hospitals NHS Foundation
Trust (Table 1). Each patient was sampled at a single
time point between d 30 and 339 after their transplant.
Ten of these patients had an active viral infection con-
ﬁrmed by detection of viral nucleic acid. Of the infected
patients, four were infected with CMV, two with
human norovirus, two with BK virus, one with CMV
and BK virus, and one with parainﬂuenza virus geno-
type 3. Two patients had chronic viral infections
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detectable for> 100 d (one patient infected with noro-
virus and one patient infected with BK virus), whereas
the remaining eight actively infected patients had a
mean duration of infection of 23.6 d. To ensure as
much as possible that sample collection coincided
with the viral infection, blood was taken within 7 d of
the most recent positive viral nucleic acid assay and
corresponding clinical symptoms if present. HSCT
Table 1. Clinical and laboratory characteristics of patients recruited post-HSCT.
Virus
infection
No virus
infection P-Value
No of patients 10 5
Sex M 4 3 0.29
Average age at HSCT 55 (15) 54 (13) 0.93
Diagnosis AML 5 2 NS
MDS 0 3
NHL 4 0
ALL 1 0
HSCT type MUD 6 4 0.62
Sib Allo 2 1
Haplo 2 0
d from HSCT 79 (63) 218 (119) 0.01
Source of stem cells Peripheral blood 10 5 NA
Condition regimen RIC 9 5 0.64
Myeloablative 1 0
Fludarabine-based Yes 9 5 1.00
conditioning No 1 0
Lymphodepletion Yes 8 4 1.00
(Campath/ATG) No 2 1
HLA mismatch 0 6 5 0.15
1 2 0
2 1 0
>2 1 0
Sex mismatch No 6 3 0.76
Mismatch 4 1
ND 0 1
Concurrent immunosuppression Yes 9 3 0.17
No 1 2
GvHD Yes 6 3 1
No 3 2
ND 1 0
CMV serostatus Pos/pos 6 0 0.07
(donor/recipient) Neg/neg 1 1
Neg/pos 0 4
Pos/Neg 3 0
EBV serostatus Pos/pos 10 5 NA
(donor/recipient)
HIV/HepB/HepC Neg/neg/neg 10 5 NA
White cell count Total 3.85 (2.27) 6.04 (2.73) 0.12
( 106/ml) Monocyte 0.32 (0.17) 0.69 (0.48) 0.007
Lymphocyte 0.62 (0.59) 0.84 (0.50) 0.47
SD is presented in brackets after the mean value, where appropriate. P-values are calculated using the v2 test as indicated. HepB:
hepatitis B; HepC: hepatitis C; M: male; AML: Acute myeloid leukaemia; MDS: Myelodysplastic syndrome; NHL: Non-Hodgkin
lymphoma; ALL: Acute lymphoblastic leukaemia; MUD: matched unrelated donor; Sib Allo: sibling allotype; Haplo: haplotype; NS:
not significant; NA: not applicable; RIC: reduced intensity conditioning; ND: not determined; Pos: positive; Neg: negative.
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patients were deﬁned as not having an active virus
infection if they exhibited no clinical symptoms suggest-
ive of viral infections, and had a negative viral nucleic
acid assay no more than 30 d from sample collection.
Samples from ﬁve healthy volunteers were also
collected.
Several clinical characteristics known to increase
susceptibility to viral infections were equally repre-
sented in infected and uninfected HSCT patients:
HSCT type, myeloablative or reduced intensity condi-
tioning, use of lymphodepletion and ﬂudarabine in the
conditioning regimen, concurrent immunosuppression,
GvHD and CMV serostatus mismatch. However, a sig-
niﬁcant diﬀerence in monocyte counts between infected
(0.32 109/l) and uninfected (0.69 109/l) patients was
identiﬁed (P¼ 0.0068), with lower monocyte counts
apparent in the infected cohort (Table 1). To avoid
bias introduced by the diﬀerence in cell counts between
the diﬀerent patient groups, CD14+ monocytes were
enriched from the peripheral blood sample by cell sort-
ing prior to RNA extraction and analysis of gene
expression. Another diﬀerence between our HSCT
patient cohorts was the time of sample collection fol-
lowing HSCT; at a median d 78 post-HSCT for infected
and median d 218 for uninfected HSCT patients. This
likely accounts the increased monocyte counts in the
uninfected HSCT patient cohort given the longer time
interval for immune reconstitution.
Up-regulation of IFN- in monocytes of patients with
active viral infections
We assessed expression of the major antiviral cytokine
IFN-a in monocytes isolated from whole-blood
samples. IFN-a expression was detected in 6/10 actively
infected HSCT patients but only 1/5 HSCT con-
trol patients and 1/5 of the healthy volunteers
(Figure 1). In addition, the IFN-a level in the actively
infected HSCT patients trended higher than control
patients and healthy volunteers, although this did not
achieve statistical signiﬁcance. Increased detection of
IFN-a in actively infected patients is in agreement with
reports that have examined IFN-a expression in the con-
text of a wide range of virus infections, from HIV to
human norovirus;21,22 IFN-a expression is up-regulated
by cells following virus recognition.
Minimal variation in expression of immune sensors
by monocytes between patients and volunteers
The innate viral sensors have been shown to be
up-regulated in response to IFN-a during viral infec-
tions in cell line and murine experiments.23 Having
identiﬁed a trend toward up-regulation of IFN-a in vir-
ally infected HSCT patients relative to uninfected
patients and healthy volunteers, we predicted a corres-
ponding increase in the expression of a panel of innate
viral sensors and signaling adaptors (RIG-I, cGAS,
IFIT1, TLR9, TRIM21, AIM2, STING and
MYD88). However, we found these genes to be consist-
ently expressed amongst HSCT patients and healthy
volunteers with no signiﬁcant increased expression in
virally infected HSCT patients (Figure 2). RIG-I,
TLR9 and IFIT1 exhibited a trend toward increased
expression (but was not statistically signiﬁcant) in
HSCT patients vs. healthy volunteers, but there was
no obvious diﬀerence between HSCT patients with or
without active infections. The innate immune sensors
each detect diﬀerent classes of virus; thus, we wanted to
assess whether sub-group analysis of the virally infected
patients by virus type would alter the results. We com-
pared gene expression in individuals infected with DNA
viruses (detected by cGAS, AIM2 and TLR9) vs. RNA
viruses (detected by RIG-I), and enveloped vs. non-
enveloped viruses (TRIM21 detects non-enveloped
viruses via bound Abs13). However, we did not identify
any obvious separation in gene expression levels using
these sub-group analyses (data not shown). A major
limiting factor here was the low number of patients in
the sub-groups. Overall, the innate immune sensors and
their signaling adaptors were expressed equally in
monocytes from HSCT patients and healthy volunteers
with no obvious up-regulation in the monocytes of
HSCT patient with active viral infections despite
increased IFN-a expression.
Variable responsiveness to IFN- stimulation of
PBMCs in vitro
To determine whether the lack of innate immune sensor
up-regulation in virally infected patients was due to an
abnormality in their ability to respond to IFN-a, we
performed in vitro stimulation experiments. PBMCs
from a subset of HSCT patients with active viral infec-
tions and PBMCs from three healthy volunteers were
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Figure 1. Gene expression of IFN-a in CD14+ monocytes by
qRT-PCR from HSCT patients with and without virus infections.
All data were normalized to b-actin (ACTB) RNA and healthy
volunteers by the delta-delta CT method of analysis. The line for
each group represents the mean.
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recovered following cryopreservation, allowed to
recover overnight in culture and then stimulated with
high-dose IFN-a (1000 IU) in vitro for 6 h. RNA was
extracted from stimulated PBMCs and gene expression
of innate immune sensors analyzed by qRT-PCR as
previously described.
We initially assessed for up-regulation of CXCL10
and IFIT1, which are known to be strongly induced
by IFN-a.24,25 This was, indeed, what we observed,
with PBMCs from actively infected HSCT patients
and healthy volunteers exhibiting an average 350-fold
increase in expression of CXCL10 and IFIT1 in
response to IFN-a (Figure 3a). This suggests that
PBMCs from HSCT patients are sensitive to IFN-a,
and validates our in vitro experimental approach.
We then proceeded to assess TRIM21, RIG-I and
cGAS expression in the same experimental system
(Figure 3b). Whereas IFN-a-stimulated PBMCs from
healthy volunteers up-regulated TRIM21 (average 3.5-
fold increase) and RIG-I (average 23-fold increase),
PBMCs from actively infected HSCT patients failed
to up-regulate TRIM21 or RIG-I, despite exogenous
IFN-a stimulation, vs. healthy volunteers (TRIM21:
P¼ 0.0016; RIG-I: P¼ 0.0001). The same trend was
observed for cGAS up-regulation of expression in
response to IFN-a stimulation; a 30-fold increase was
observed in healthy volunteers vs. only a twofold
increase in HSCT patients with active viral infections
(diﬀerence not statistically signiﬁcant). This reduced
up-regulation of innate immune sensors is not due to
a global insensitivity to IFN-a since the HSCT patient
PBMCs were able to up-regulate CXCL10 and IFIT1.
Evaluation of effect of immunosuppression on
response to IFN-
A suggested cause for the lack of up-regulation of
the innate immune receptors in HSCT patient mono-
cytes and in vitro-stimulated PBMCs could be due
to the immunosuppressive therapy regimens altering
IFN-a signaling pathways.26,27 At the time of sample
collection, 7/10 actively infected HSCT patients
were receiving calcineurin inhibitors (tacrolimus/
ciclosporin), and 2/10 of these patients were also
cGAS TLR9 AIM2
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Figure 2. Gene expression of innate immune viral sensors and adaptors. Gene expression was analyzed by qRT-PCR of CD14+
monocytes from HSCT patients with and without virus infections. All data were normaliszed to b-actin (ACTB) RNA and healthy
volunteers by the delta-delta Ct method of analysis. The line for each group represents the mean.
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receiving methylprednisolone for GvHD. Two of ﬁve
HSCT patients with no active infection were receiving
tacrolimus and 1/5 receiving prednisolone. In addition,
PBMCs used for the in vitro stimulation experiments
were all from HSCT patients that were receiving a cal-
cineurin inhibitor. To investigate the possibility that
calcineurin inhibitors could account for the discrepancy
in innate virus sensor expression pattern in HSCT
patients, we cultured PBMCs from healthy volunteers
in the presence or absence of tacrolimus. The target
therapeutic range for whole-blood tacrolimus in patients
was between 5 and 15ng/ml (median 10ng/ml); there-
fore, PBMCs were incubated with or without 10ng/ml
tacrolimus for 2 h prior to stimulation with 1000 IU
IFN-a or the equivalent volume of PBS for 4 h. RNA
was then extracted from PBMCs and gene expression
analyzed by qRT-PCR.
In IFN-a-unstimulated PBMCs, tacrolimus treat-
ment resulted in down-regulation of CXCL10 and
TNF-a by 50%, but had no eﬀect on the expression
level of the innate immune receptors cGAS, RIG-I
and TRIM21 (Figure 4a). In response to IFN-a stimu-
lation, we observed robust up-regulation of ISGs,
including cGAS, RIG-I and TRIM21, which was not
aﬀected by tacrolimus treatment (Figure 4b). This
shows that in PBMCs, innate virus sensor induction
by IFN-a is unaﬀected by tacrolimus.
PBMCs from virally infected primary immunodefi-
ciency patients up-regulate innate viral sensors
We wanted to assess whether the loss of IFN-a-induced
up-regulation of innate immune sensors in HSCT
patients with active viral infections was speciﬁc to the
HSCT treatment or a consequence of viral infection. To
investigate this, we tested PBMCs from ﬁve patients
with primary immunodeﬁciency that required long-
term intravenous immunoglobulin or subcutaneous
immunoglobulin therapy for recurrent viral infections
(‘PI patients’). All ﬁve PI patients had conﬁrmed active
viral infections; one norovirus, two parainﬂuenza, and
two rhinovirus infections.
PBMCs isolated from PI patients with active infec-
tions retained the ability to up-regulate CXCL10,
IFIT1, RIG-I, TRIM21 and cGAS in response to in
vitro IFN-a stimulation (Figure 5). Although RIG-I
was expressed at lower levels in PBMCs from PI
patients with active viral infections following IFN-a
stimulation, this still amounted to a 10-fold up-regula-
tion of expression vs. unstimulated PBMCs (depicted
by the horizontal line at y¼ 1). This is in contrast to the
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PBMCs from actively infected HSCT patients, where
the expression of RIG-I and TRIM21 did not change
in response to IFN-a stimulation, and cGAS expression
was only up-regulated twofold.
Discussion
Virus infections are a common cause of mortality in
allogenic HSCT patients, but risk factors that increase
the likelihood of succumbing to virus infection in these
patients are poorly deﬁned. Post-HSCT, the adaptive
immune response is severely impaired owing to the time
taken to reconstitute a functional lymphocyte popula-
tion and the use of immunosuppressive therapies.
Our HSCT patient population has several risk factors
for viral infections, including the use of ﬂudarabine
conditioning regimens and lymphodepletion with alem-
tuzumab or ATG, both contributing to a delayed
immune reconstitution. Therefore, the innate immune
system must play an important role in protecting
patients from virus infections during this period.
Several new innate immune viral sensors have recently
been identiﬁed, but their importance in human popula-
tions has not been evaluated in detail. We therefore
wanted to characterize the expression of the newly dis-
covered viral sensors in HSCT patients, and assess
whether diﬀerences between virally infected and unin-
fected patients could contribute to susceptibility to
virus infections.
We ﬁrst analyzed gene expression in CD14+ mono-
cytes from 10 virally infected HSCT patients, ﬁve unin-
fected HSCT patients and ﬁve healthy volunteers. We
observed a trend towards increased IFN-a expression
in monocytes from virally infected HSCT patients.
However, this did not translate to increased ISG
expression, with the innate immune viral sensors
cGAS, RIG-I, TRIM21, IFIT1 and AIM2, and the
adaptor proteins MYD88 and STING, expressed at
similar levels between infected and uninfected HSCT
patients, and healthy volunteers. We proceeded to func-
tionally test the ability of HSCT patient PBMCs to
respond to IFN-a stimulation. We found that PBMCs
from virally infected HSCT patients were unable to up-
regulate the innate immune viral sensors RIG-I and
TRIM21 in response to IFN-a. Thus, the in vitro data
mirror the in vivo ﬁnding from HSCT patient mono-
cytes. This is despite using a mixed-cell population of
PBMCs for the in vitro stimulation experiments (due to
sample availability), but suggests a possible global
defect in the IFN-a immune response across multiple
cell types. We have shown that this apparent insensitiv-
ity to IFN-a was not due to the eﬀect of calcineurin
inhibitors as treating healthy volunteer PBMCs with
tacrolimus did not inhibit up-regulation of the ISGs
following IFN-a stimulation. PBMCs from virally
infected patients with primary immunodeﬁciency exhib-
ited IFN-a sensitivity with ISG up-regulation in a simi-
lar manner to healthy volunteers, suggesting the
apparent failure to up-regulate the innate immune
viral sensor genes is speciﬁc to HSCT patients.
To the best of our knowledge, this is the ﬁrst time
that expression of these innate immune viral sensors
have been analyzed in PBMCs from HSCT patients.
Our ﬁndings demonstrate that these genes are actively
expressed and detectable. However, the failure of
actively infected HSCT patient monocytes and
PBMCs to up-regulate the innate immune viral sensors
despite IFN-a stimulation was unexpected. This did not
represent a global deﬁciency in the cellular response to
IFN-a, as CXCL10 and IFIT1 that are known to be
strongly up-regulated in response to IFN-a were indeed
up-regulated in PBMCs from all patients examined.
What might be the cause for this apparent defective
IFN-a response in the immune innate sensors in virally
infected HSCT patients? As 7/10 actively infected
HSCT patients were receiving calcineurin inhibitors as
part of their GvHD prophylaxis, we assessed whether
immunosuppression could play a role in suppressing
the IFN-a response in the monocytes. Tacrolimus inhi-
bits the phosphorylase activity of calcineurin, which, in
turn, inhibits the transcription factor NFAT required
for transcriptional activation of IL-2. IL-2 is a key
growth factor for T cells; therefore, it has been under-
stood that the immunosuppressive eﬀect of tacrolimus
is achieved primarily through T-cell suppression.27
Nevertheless, a number of recent studies have shown
NFAT can be expressed in innate immune cells,28 and
tacrolimus can aﬀect these innate immune cells
by changing the expression of immunomodulatory
cytokines.27,29 Our results add support to these obser-
vations by showing that tacrolimus reduced the expres-
sion of TNF-a and CXCL10 in PBMCs pretreated with
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Figure 5. Analysis of effect of virus infection on ISG expression
in patients with primary immunodeficiency (PI). Gene expression
was analyzed by qRT-PCR in patients with and without active
virus infections in PBMCs stimulated by IFN-a in vitro. All data
were normalized to b-actin (ACTB) RNA and un-stimulated
patient PBMCs by the delta-delta CT method of analysis.
Volunteers n¼ 3; actively infected primary immunodeficiency
patients n¼ 5. Dotted horizontal line at y¼ 1 corresponds to no
change in mRNA expression relative to unstimulated PBMCs.
**P¼ 0.001–0.01. NS: not significant.
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tacrolimus, in line with previous reports.27,30 However,
TNF-a and CXCL10 expressions were still able to be
up-regulated by IFN-a stimulation, suggesting IFN-a
signaling pathways are independent of the eﬀect of
tacrolimus. However, in addition we have shown that
tacrolimus does not aﬀect the basal expression levels of
the innate immune virus sensors (RIG-I, cGAS,
TRIM21 and IFIT1), and that IFN-a signaling path-
ways are not disrupted by tacrolimus. Therefore, calci-
neurin inhibition is not the cause of the defective IFN-a
response observed in virally infected HSCT patients.
We have also demonstrated that the defective IFN-a
response is not simply a consequence of viral infection
as PBMCs from primary immunodeﬁciency patients
with viral infections were able to up-regulate innate
immune viral sensors. This suggests that the failure
to up-regulate the innate viral sensors could be speciﬁc
to allogeneic HSCT treatment. There have been other
studies that have also found a functional defect in
monocytes after allogeneic HSCT,31,32 and epigenetic
changes in the regulation of the innate immune
system have been suggested as a potential cause.33 In
our study, the infected HSCT patients did have a lower
monocyte count than uninfected HSCT patients, which
could have contributed to increased susceptibility to
viral infections. However, our gene expression analysis
used puriﬁed monocytes, which would have normalized
the diﬀerence in monocyte count between infected and
uninfected HSCT patients. Samples collected from
uninfected HSCT patients were, on average, at a later
time point following HSCT than infected HSCT
patients (218 d vs. 79 d post-HSCT). Therefore, we
cannot exclude the possibility that the defective
IFN-a response is transient and only aﬀects the early
phase post-HSCT. Our data therefore suggest it is an
as-yet-undeﬁned characteristic of actively infected
HSCT patients that impairs their ability to up-regulate
the innate immune viral sensors in response to IFN-a.
The main limitations of our study were ﬁrstly only
sampling the patients at a single time point. For
actively infected HSCT patients, we are therefore
unable to conclude whether the defective IFN-a
response preceded the viral infection, or occurred
during viral infection, and whether the monocytes
regained full IFN-a sensitivity after the resolution of
the viral infection. A time course analysis of HSCT
patient monocytes will allow us to address these ques-
tions, and give further insight into whether such a
defective IFN-a response could increase susceptibility
to viral infections. Future studies should aim to look at
speciﬁc immune cell types, and possibly non-immune
cell innate viral sensor responses to IFN-a and viral
infection in HSCT patients. Lastly, access to a larger
cohort of patients would have allowed more detailed
characterization of the innate immune response to dif-
ferent viruses, and how diﬀerent patient and transplant
characteristics could have aﬀected the IFN-a response.
To conclude, this study provides a valuable, initial
insight into the intracellular antiviral immune responses
of HSCT patients. It has been demonstrated that IFN-a
signaling is varied and complicated in this patient
cohort, and we have provided preliminary evidence
that the ability of HSCT patients to up-regulate anti-
viral ISGs in the face of viral infection is impaired. This
could be a useful clinical biomarker to predict suscep-
tibility to viral infections after HSCT, as well as a
potential therapeutic opportunity if mechanisms exist
to enhance the innate immune viral sensor expression.
Therefore, further studies to investigate IFN-a signal-
ing pathways in response to virus infection in clinical
patients are warranted.
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